BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma - BeiGene Australia

Australia
- Australia
- Canada EN|FR
- China
- Germany
- Global
- Spain
- US

https://ir.beigene.com/news-details/?id=cc55645e-f740-4aac-a9d7-350625f948cc

You will be redirected to

Click the link above to continue or CANCEL